Callahan Advisors LLC Grows Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Callahan Advisors LLC increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 10.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 35,719 shares of the medical research company’s stock after purchasing an additional 3,506 shares during the quarter. Callahan Advisors LLC’s holdings in IQVIA were worth $7,019,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new position in IQVIA in the third quarter valued at about $27,000. Synergy Asset Management LLC purchased a new position in IQVIA in the fourth quarter valued at about $33,000. Avior Wealth Management LLC boosted its stake in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the last quarter. Assetmark Inc. boosted its stake in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the last quarter. Finally, Concord Wealth Partners purchased a new position in IQVIA in the third quarter valued at about $57,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

IQVIA stock opened at $193.65 on Tuesday. The firm’s 50 day simple moving average is $200.15 and its 200 day simple moving average is $217.43. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $35.15 billion, a PE ratio of 25.82, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts expect that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Barclays dropped their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Truist Financial reissued a “buy” rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Finally, Morgan Stanley boosted their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $251.67.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.